Questioning the association between bisphosphonates and atypical femoral fractures - Wikidata - wikimedia - TriplyDB

Questioning the association between bisphosphonates and atypical femoral fractures

Questioning the association between bisphosphonates and atypical femoral fractures

http://www.wikidata.org/entity/Q34899110

about

The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.[Periprosthetic fractures following total hip and knee arthroplasty: Risk factors, epidemiological aspects, diagnostics and classification systems].

P2860

Q38611601-0D5A25AB-16A2-4BBA-9E71-B3F0032A6453 Q40904738-21D1EDE3-22A9-47FA-A664-E88914E6E02E

P2860

Questioning the association between bisphosphonates and atypical femoral fractures

http://www.wikidata.org/entity/Q34899110

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Questioning the association between bisphosphonates and atypical femoral fractures

@ast

Questioning the association between bisphosphonates and atypical femoral fractures

@en

Questioning the association between bisphosphonates and atypical femoral fractures

@nl

type

label

Questioning the association between bisphosphonates and atypical femoral fractures

@ast

Questioning the association between bisphosphonates and atypical femoral fractures

@en

Questioning the association between bisphosphonates and atypical femoral fractures

@nl

prefLabel

Questioning the association between bisphosphonates and atypical femoral fractures

@ast

Questioning the association between bisphosphonates and atypical femoral fractures

@en

Questioning the association between bisphosphonates and atypical femoral fractures

@nl

P1433

Q34899110-E6718FF8-83A0-4EE1-B1E5-21257C8394BF

P1476

Q34899110-544CB30A-18FB-4CE5-9B8F-A1B6EFC72D95

P2093

Q34899110-1EA46764-D995-4FFD-851C-7AFA227EDA9A

Q34899110-302360BA-9423-442B-A0DB-418D8763994D

Q34899110-48F3748B-127A-49C1-9B59-FB468B9FB6C1

Q34899110-4CF5D35B-5199-4E28-97A2-D3C7597FE22D

Q34899110-9C6D6842-0528-4B9F-B497-5BC16C8F396C

Q34899110-FF7C718B-106C-46F7-9A6A-1F1B2D2417D1

P2860

Q34899110-003839B6-F9EC-4E6E-AD2F-DD75DA5B3012

Q34899110-0486907A-7010-426B-A808-0A226A46DB87

Q34899110-0FD7F150-CBED-4B20-ADCA-D1E6E9970057

Q34899110-1808168B-D62B-409F-B4D2-39AE1C3D9251

Q34899110-1B8617EA-678F-4FF8-810C-0657DD31E6BE

Q34899110-1C14C037-B55B-4755-B0B2-233F566D5D2D

Q34899110-227303B2-7ADB-4DC6-B492-9DF5FD1798C0

Q34899110-23AB9933-6B14-4B4A-94A6-BAC61F7D81FE

Q34899110-2C9B7099-5B72-4538-AA9F-D40F74D2D480

Q34899110-3215972E-5C0E-4B23-BA92-F80E185A2A6C

P304

Q34899110-478BC987-BAB6-450F-92CB-2E124DC9BEAF

P31

Q34899110-48B2E25E-6E35-4438-BA3F-19AEDEA53D01

P356

Q34899110-41F38387-C144-48A9-B5F7-5AA0761C53D7

P407

Q34899110-629249B8-327B-489D-B58A-E4928EB4EDC8

P478

Q34899110-4ACDDEE2-37A7-429F-8E1D-0540B1607EB6

P577

Q34899110-D3A26F81-E842-4CA9-A13B-195E8249CF3C

P5875

Q34899110-BE3C5065-9731-46D6-973D-7C2783C017AA

P698

Q34899110-4236C8D8-38E3-49A1-88F3-3343721FE656

P932

Q34899110-A3AB738B-FF83-4DA7-898E-D067FC589B10

P356

P1433

Annals of the New York Academy of Sciences

P1476

Questioning the association between bisphosphonates and atypical femoral fractures

@en

P2093

Li Sun

http://www.w3.org/2001/XMLSchema#string

Michael Pazianas

http://www.w3.org/2001/XMLSchema#string

Mone Zaidi

http://www.w3.org/2001/XMLSchema#string

Se-min Kim

http://www.w3.org/2001/XMLSchema#string

Sol Epstein

http://www.w3.org/2001/XMLSchema#string

Tony Yuen

http://www.w3.org/2001/XMLSchema#string

P2860

Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.

Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).

Severely suppressed bone turnover: a potential complication of alendronate therapy.

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Relating micromechanical properties and mineral densities in severely suppressed bone turnover patients, osteoporotic patients, and normal subjects

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/NYAS.12551

http://www.w3.org/2001/XMLSchema#string

P407

P478

1335

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266563873

http://www.w3.org/2001/XMLSchema#string

P698

25294742

http://www.w3.org/2001/XMLSchema#string

P932

4289441

http://www.w3.org/2001/XMLSchema#string